Erlotinib [cytosol]

Stable Identifier
Tarceva, OSI-774, Reversible tyrosine kinase inhibitor erlotinib EGFR specific
Locations in the PathwayBrowser

Erlotinib (OSI-774, Tarceva) is an EGFR-specific tyrosine kinase inhibitor (TKI) from the anilinoquinazoline class of TKIs, developed by OSI/Genentech. Erlotinib competitively inhibits binding of ATP to kinase domain of EGFR, thereby preventing EGFR autophosphorylation and downstream signaling, which halts proliferation of EGFR-dependent tumor cells (Moyer et al. 1997 , Stamos et al. 2002).

Literature References
PubMed ID Title Journal Year
12196540 Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

Stamos, J, Sliwkowski, MX, Eigenbrot, C

J Biol Chem 2002
9354447 Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

Reynolds, MM, Neveu, M, DiOrio, C, Boman, B, Barbacci, EG, Doty, J, Moyer, JD, Iwata, KK, Pustilnik, LR, Pollack, VA, Sloan, D, Arnold, L, Miller, P, Moyer, MP, Morin, MJ, Theleman, A, Cunningham, A

Cancer Res 1997
External Reference Information
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Pharos - Ligands
Cite Us!